ALPHA
Weight Loss & GLP-1s · 17 min · 3,242 words

CagriSema vs Tirzepatide for Obesity: What the Head-to-Head Trial Actually Showed

Novo Nordisk ran the trial everyone wanted: CagriSema against full-dose tirzepatide, 84 weeks, no placebo. Tirzepatide won. What that does and does not settle matters more than the headline.

CagriSema vs Tirzepatide for Obesity: What the Head-to-Head Trial Actually Showed

For two years the comparison was made the lazy way. Someone put CagriSema's 68-week result from its pivotal trial next to tirzepatide's 72-week result from its own pivotal trial, saw two numbers that both started with a 20, and called it a tie. Then the direct comparison came in, and it was not a tie. The direct trial is the better evidence, and it points one way. It also has real limits: it was open-label, it has only been reported in a press release, and it tested one dose of each drug in one population.

This piece goes through what was measured, what was not, where CagriSema stands with the FDA as of early November 2026, and what any of it means if you are a man deciding on a weight-loss drug now rather than in some hypothetical future.

Recommended

Starting from

$77/mo

Free consultation

DudeMeds logo

3.9 AHF · 3.2 Trustpilot

Uses commercial-grade injectable testosterone rather than compounded, with labs, medication and consultations in one $77 monthly price. Four published reviews, so the offer is stronger than the evidence behind it.

Get Started Free

What REDEFINE 4 tested, and what it found

REDEFINE 4 randomised 809 adults with obesity and at least one weight-related comorbidity to once-weekly CagriSema 2.4 mg/2.4 mg or once-weekly tirzepatide 15 mg, and followed them for 84 weeks [1]. CagriSema is two drugs in one injection: cagrilintide, a long-acting amylin analogue, and semaglutide, the GLP-1 receptor agonist in Wegovy. Tirzepatide, sold as Zepbound for weight, acts on both GIP and GLP-1 receptors. Mean baseline weight was 114.2 kg, roughly 252 lb, which is heavier than the populations in either drug's pivotal trial [1].

The registry entry shows the design was built to test non-inferiority. The single primary outcome is listed as "to confirm non-inferiority of CagriSema versus tirzepatide: relative change in body weight" at week 84, and the study was unmasked: no blinding of participants, investigators or assessors [2]. Novo's own trial design asked a modest question. It was not trying to show CagriSema was better, only that it was not meaningfully worse.

It failed that test. Novo's 23 February 2026 announcement reports [1]:

  • Treatment-regimen estimand (everyone randomised, whether or not they stayed on the drug): CagriSema 20.2% weight loss, tirzepatide 23.6%.
  • Efficacy estimand (as if everyone had adhered to treatment, regardless of dose changes): CagriSema 23.0%, tirzepatide 25.5%.

The release states plainly that the trial "did not achieve its primary endpoint of demonstrating non-inferiority on weight loss" [1]. It does not disclose the non-inferiority margin, the confidence interval around the difference, discontinuation rates, or adverse-event rates by arm. On safety, the release says only that the most common adverse events with CagriSema were gastrointestinal, mostly mild to moderate, and diminished over time [1]. That says nothing about how CagriSema compared to tirzepatide.

A gap of 3.4 percentage points on the intention-to-treat measure sounds small. On a 250 lb man it is about 8.5 lb, and it comes from a trial Novo itself designed only to show CagriSema was not worse. That should move your expectations.

Why the open-label design and the estimands matter

Two methodological details deserve more attention than they got in the coverage, and they cut in different directions.

Open-label is a real limitation, and it probably does not rescue CagriSema. When participants and doctors know which drug is being given, behaviour changes. People may stick with a drug they know by reputation and drop one that is investigational more readily, and prescribers may handle side effects differently. Tirzepatide was already on the US market when REDEFINE 4 enrolled. CagriSema had not been approved anywhere. If brand familiarity improved adherence on the tirzepatide arm, the treatment-regimen gap would be inflated by behaviour rather than pharmacology.

The efficacy estimand partly addresses this, because it models what happens if everyone adheres. Tirzepatide still came out 2.5 points ahead on that measure [1]. So the open-label design may have widened the gap, but it does not explain the gap away. Weight is also an objective endpoint, which limits how much knowing the treatment can bias the measurement itself. Unblinding matters more for subjective outcomes like nausea severity than for a number on a scale.

The titration schedules differed. The registry shows a 16-week dose-escalation period for CagriSema and a 20-week period for tirzepatide [2]. Faster escalation tends to mean more gastrointestinal side effects early, which can push people to hold their dose down. That could disadvantage CagriSema slightly. It could also reflect the reality of how each drug is used. Without the full paper there is no way to tell how many people on each arm reached and stayed on the top dose.

That last point is not a footnote. In REDEFINE 1, the placebo-controlled trial behind the FDA filing, the protocol let participants change their dose throughout the study. At week 68, only 57.3% of people on CagriSema were on the full 2.4 mg/2.4 mg dose, against 82.5% on cagrilintide alone and 70.2% on semaglutide alone [5]. Fewer people stayed on the full CagriSema dose than on either of its two components alone. That is a tolerability signal. If REDEFINE 4 shows a similar pattern when its full data are published, it would explain part of the gap and it would matter in practice, because a dose you cannot tolerate does not help you.

Where CagriSema stands with the FDA in November 2026

CagriSema is not approved in the United States. Novo submitted it to the FDA for weight management in December 2025, based on REDEFINE 1 and REDEFINE 2, the two placebo-controlled trials [1]. REDEFINE 4 was not part of that submission.

Novo's financial report for the first nine months of 2026, published 4 November, still lists the US decision as a fourth-quarter 2026 milestone. CEO Mike Doustdar describes the company as "preparing for the US launch of CagriSema in early 2027, subject to regulatory approval" [3]. The same report says Novo has filed for approval in China, with the review expected to finish in the first half of 2028 [3].

So, as of the date this was written, you cannot be prescribed CagriSema outside a clinical trial. The best case is an FDA approval in the last weeks of 2026 and pharmacy availability sometime in 2027. We have not assumed an approval and will not report one until it happens. Any website currently offering "CagriSema" for sale is not offering an approved drug.

Two other milestones on Novo's timetable matter for anyone weighing the drug long-term. REDEFINE 3, the cardiovascular outcomes trial of about 7,000 people, is not scheduled to report until the second half of 2027. REDEFINE 11, another placebo-controlled weight trial with an 80-week extension, is due in the first half of 2027 [1][3]. Until REDEFINE 3 reads out, CagriSema has no cardiovascular outcome data of its own.

REDEFINE 1 vs SURMOUNT-1: the comparison that misled everyone

This is the comparison that circulated for most of 2025, and it is worth taking apart because the same mistake will be made with the next drug.

REDEFINE 1 enrolled 3,417 adults without diabetes, randomised 21:3:3:7 to CagriSema, semaglutide alone, cagrilintide alone or placebo, for 68 weeks. On the treatment-policy estimand, CagriSema produced a 20.4% mean weight loss against 3.0% on placebo. That is a real and large effect, published in the New England Journal of Medicine [4]. Gastrointestinal adverse events affected 79.6% of people on CagriSema against 39.9% on placebo, mostly transient and mild to moderate [4].

SURMOUNT-1, tirzepatide's pivotal obesity trial, enrolled 2,539 adults without diabetes and ran 72 weeks. On the treatment-regimen estimand, tirzepatide 15 mg produced a 20.9% mean weight loss against 3.1% on placebo, with a mean baseline weight of 104.8 kg [6].

Put side by side, 20.4% and 20.9% look identical. That is why so many people called the two drugs equivalent before the direct trial reported. The problem is that cross-trial comparisons hide everything that differs between trials: the populations, the countries, the dose-flexibility rules, the length of follow-up, the year, and the lifestyle support. A difference that small between two separate trials tells you almost nothing.

REDEFINE 4 put both drugs in the same trial, and a 3.4-point gap appeared that the cross-trial comparison could not show [1]. Notice the pattern. CagriSema's REDEFINE 4 result, 20.2%, is almost exactly its REDEFINE 1 result. Tirzepatide's REDEFINE 4 result, 23.6%, is meaningfully higher than its SURMOUNT-1 result. The trials ran different lengths with heavier participants, so read nothing causal into that. But it is a useful reminder that a drug's pivotal-trial number is not a fixed property of the drug.

There is a second, more revealing cross-check. In SURMOUNT-5, an open-label head-to-head in adults with obesity, tirzepatide at the maximum tolerated dose produced a 20.2% weight loss against 13.7% for semaglutide at the maximum tolerated dose over 72 weeks [7]. That is a 6.5-point advantage over semaglutide alone. In REDEFINE 1, adding cagrilintide to semaglutide improved weight loss from 14.9% to 20.4% on the treatment-policy estimand, about 5.5 points [5]. Different trials, so treat this as arithmetic rather than evidence. But both point the same way. GIP co-agonism appears to add slightly more weight loss on top of GLP-1 than amylin does at these doses. REDEFINE 4 is consistent with that rather than surprising.

The diabetes trials complicate the picture in a useful way

Novo also ran CagriSema against tirzepatide in type 2 diabetes, and those results show why "which drug wins" depends on dose and population.

In REDEFINE 2, the placebo-controlled diabetes trial in the FDA filing, CagriSema produced a 13.7% weight loss against 3.4% on placebo over 68 weeks [8]. Weight loss is typically smaller in people with diabetes on every drug in this class, so the lower number is expected.

REIMAGINE 4 compared CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg over 68 weeks in about 1,000 people with type 2 diabetes on metformin, with or without an SGLT2 inhibitor. It was also open-label [9][10]. It had two primary endpoints. CagriSema was non-inferior on weight, with 15.2% against 15.8% on the efficacy estimand. It was not non-inferior on HbA1c: 1.9 percentage points against 2.2 for tirzepatide [9]. In plain terms, CagriSema matched tirzepatide on weight in diabetes but fell short on blood sugar, which is the main reason someone with diabetes is prescribed either drug.

REIMAGINE 5 is the trial Novo has promoted as CagriSema beating tirzepatide. It compared the lower CagriSema dose, 1.0 mg/1.0 mg, with tirzepatide 5 mg in adults with type 2 diabetes and obesity. At week 60, CagriSema produced 12.4% weight loss against 9.1% and was non-inferior on HbA1c [3]. That is a legitimate result, but look at the comparator. Five milligrams is tirzepatide's lowest maintenance dose. Under the label, 2.5 mg is a starting dose only, and maintenance is 5, 10 or 15 mg [11]. Beating the bottom rung of a competitor's dose ladder is a statement about low-dose positioning, not about which drug is stronger.

Novo's argument, from its own materials, is that many patients never reach or stay on the highest dose, so lower-dose comparisons reflect real-world use [3]. There is something to that. It is also the argument a company makes after losing at full dose. Both readings can be true. Novo also reports 21% weight loss at 68 weeks for CagriSema 1.0 mg/1.0 mg in REDEFINE 9, a placebo-controlled obesity trial [3]. If that holds up in a peer-reviewed paper, a lower-dose CagriSema with better tolerability could be clinically useful even if it never beats tirzepatide 15 mg.

What we still do not know

This section matters as much as the results, because most of what would decide the question for an individual is not yet public.

  • No peer-reviewed REDEFINE 4 paper. Everything above comes from Novo's announcement and the registry [1][2]. We could not find a published paper as of early November 2026. The non-inferiority margin, confidence intervals, discontinuation rates, adverse events by arm and dose-attainment data are all missing.
  • No head-to-head tolerability data. The question that matters most in daily life, which drug people can stay on, is exactly the one the press release does not answer.
  • No cardiovascular outcome data for CagriSema. REDEFINE 3 is not expected until the second half of 2027 [3].
  • No direct data on lean mass, maintenance after stopping, or men specifically. None of the headline releases break results out by sex, and none of the head-to-head trials has published body-composition data.
  • No head-to-head at a higher CagriSema dose. Novo has said it plans a trial of a higher-dose version, 2.4 mg cagrilintide with 7.2 mg semaglutide [1]. The comparison may look different if that dose works and is tolerated, but that is a hypothesis, not a result.

Anyone who tells you CagriSema is "better" or "about the same" as tirzepatide right now is filling these gaps with confidence they do not have.

What this means if you are choosing now

The practical answer is simpler than the science. Tirzepatide is the better choice today, for two independent reasons: it is the only one of the two you can be prescribed, and in the only direct comparison it produced more weight loss. Neither reason depends on the other.

Zepbound is FDA-approved to reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related condition, and to treat moderate to severe obstructive sleep apnoea in adults with obesity [11]. The labelled schedule starts at 2.5 mg weekly for four weeks, then 5 mg, rising in 2.5 mg steps no sooner than every four weeks to a maintenance dose of 5, 10 or 15 mg [11]. It carries a boxed warning about thyroid C-cell tumours seen in rats and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [11]. Those are the same class warnings that will apply to CagriSema's semaglutide component.

If you are starting from scratch, the useful step is finding a prescriber who will titrate properly and monitor you, not waiting for CagriSema. Our weight management treatment guide covers the drug options and what a sensible monitoring plan looks like. If you want to compare online weight-loss providers side by side, that page lays out pricing and what each platform prescribes.

For an established telehealth route, PeterMD offers semaglutide and tirzepatide programmes with labs. Sesame Care gets you a single visit with a named doctor at a published price, which suits someone who wants an opinion before committing to a subscription.

There is a reasonable case for being on the CagriSema waiting list, and it is narrower than the marketing will suggest. If you have done well on semaglutide but plateaued, and you have tolerated it without much trouble, adding amylin is the logical next step once it is approved. REDEFINE 1 showed the combination clearly outperforms semaglutide alone [4]. If tirzepatide has given you side effects you cannot live with, a different mechanism is worth trying. Those are real use cases. "I want the newest drug" is not one of them.

If you have type 2 diabetes, the current evidence tilts further toward tirzepatide at full dose, because REIMAGINE 4 missed non-inferiority on HbA1c [9]. Glucose control is the outcome that protects your eyes, kidneys and nerves, so a drug that matches on weight but falls short on HbA1c is the weaker choice for you.

Other platforms worth comparing include Hims, Roman and Strut Health. Each differs in which drugs it prescribes, whether it uses branded or compounded product, and how closely it supervises titration. Ask that directly before you sign up. If you would rather have someone in the room, a local medical weight-loss clinic can supervise the same titration in person.

For background on how tirzepatide stacks up against the drug CagriSema is built on, see tirzepatide vs semaglutide for men's fat loss. For the other next-generation contender, read retatrutide vs tirzepatide. If cost is driving you toward a compounded product, compounded tirzepatide vs Zepbound covers what actually differs.

The bottom line: CagriSema is a real advance over semaglutide alone and will probably be approved. It is not an advance over tirzepatide, on the only evidence that compared them directly. Tirzepatide wins on the data we have, by a margin that matters on the scale. The open questions about tolerability and outcomes are genuine, and they are reasons to watch for the full paper, not reasons to wait.

Frequently asked questions

Is CagriSema FDA-approved?

Not as of early November 2026. Novo Nordisk submitted it for weight management in December 2025, and its 4 November 2026 financial report still lists the US decision as a fourth-quarter 2026 milestone, with launch "in early 2027, subject to regulatory approval" [3]. Until approval, the only legitimate way to receive it is in a clinical trial.

Did CagriSema beat tirzepatide in any trial?

Only at low doses. In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg produced more weight loss than tirzepatide 5 mg in people with type 2 diabetes, 12.4% against 9.1% at week 60 [3]. At full doses, tirzepatide produced more weight loss in REDEFINE 4 [1] and better HbA1c reduction in REIMAGINE 4 [9].

Is CagriSema just semaglutide with something added?

Essentially, yes. It is semaglutide 2.4 mg, the dose in Wegovy, co-administered with cagrilintide 2.4 mg, an amylin analogue. Amylin is a hormone released with insulin that slows stomach emptying and increases fullness. In REDEFINE 1, the combination produced 20.4% weight loss against 14.9% for semaglutide alone on the treatment-policy estimand [5].

Why did fewer people stay on the full CagriSema dose?

The REDEFINE 1 protocol allowed dose changes throughout, and at week 68 only 57.3% of CagriSema participants were on the full dose, compared with 70.2% on semaglutide alone [5]. Gastrointestinal adverse events were common, affecting 79.6% on CagriSema [4]. Novo has not published comparable dose-attainment data for REDEFINE 4.

Should I wait for CagriSema instead of starting tirzepatide?

For most men, no. Tirzepatide is approved and available, and it produced more weight loss in the only direct comparison [1][11]. Waiting makes sense only if you have a specific reason to avoid tirzepatide and a prescriber who agrees, and even then there is no guaranteed approval date.

Sources

A

Alpha Health Finder Editorial Team

Editorial Team

The Alpha Health Finder editorial team researches and writes evidence-based men's health content. Articles are grounded in cited primary sources and reviewed against a fixed editorial standard before publication. We are a research and directory team — not your prescribing clinicians.

More from Alpha →

Looking for an online provider?

Find a qualified online provider — compare options vetted and reviewed by Alpha Health Finder.

Alpha Journal

One email a week. The research, not the hype.

What we published this week, what we changed our minds about, and what it means if you are on a protocol.

No spam, no selling your address. Unsubscribe in one click.

Take the next step

Featured Online Provider

DudeMeds logo
3.9

AHF editorial rating

3.2 on Trustpilot, 4 reviews

Uses commercial-grade injectable testosterone rather than compounded, with labs, medication and consultations in one $77 monthly price. Four published reviews, so the offer is stronger than the evidence behind it.

Also treats

Injectable Testosterone Therapy · Enclomiphene Therapy · Erectile Dysfunction Treatment · Hair Loss Treatment · GLP-1 Weight Loss · Male Fertility Support

Starting at
$77/mo
Consultation
Free
Coverage
All 50 States
Turnaround
2-5 Days
Continue reading
Survodutide vs Tirzepatide for Visceral Fat: What Has Actually Been Measured
Weight Loss & GLP-1s · 13 min

Survodutide vs Tirzepatide for Visceral Fat: What Has Actually Been Measured

Survodutide is widely expected to beat tirzepatide on visceral fat, and the reasoning behind that expectation is genuinely good. The problem is that nobody has measured it. Not in a head-to-head, and not in survodutide's own trials.

Nov 5, 2026
Share
Survodutide vs Semaglutide
Weight Loss & GLP-1s · 16 min

Survodutide vs Semaglutide for Obesity: What the 2026 Evidence Actually Shows

Survodutide, a glucagon/GLP-1 dual agonist from Boehringer Ingelheim, now has phase 3 data demonstrating average weight loss of up to 13.1% in people with type 2 diabetes and clinically significant reductions in people without diabetes — putting it in the same tier as Wegovy…

Oct 23, 2026
Share
Weight Loss & GLP-1s · 14 min

Retatrutide vs. Tirzepatide: Which Triple Agonist Actually Wins in 2026?

Retatrutide produces greater peak weight loss than tirzepatide in clinical data — roughly 24.2% body weight reduction at 48 weeks versus tirzepatide's 22.5% at 72 weeks — but calling it "better" depends entirely on what a researcher or clinician means by that word.

Sep 18, 2026
Share
Weight Loss & GLP-1s · 15 min

How Much Protein Should You Eat on Ozempic or Zepbound?

Adults taking semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound) should target 1.2–1.6 grams of protein per kilogram of reference body weight per day — roughly double the standard dietary recommendation — to preserve lean mass during pharmacologically induced weight loss.

Sep 9, 2026
Share